Skip to main content
OpenTrials

Clinical trial condition

Metastatic Castration-resistant Prostate Cancer (mCRPC)

Explore clinical trials studying Metastatic Castration-resistant Prostate Cancer (mCRPC). Study availability and eligibility vary by location and protocol.

34 public trials 11 recruiting studies
Refine in advanced search Browse all conditions

Metastatic Castration-resistant Prostate Cancer (mCRPC) trial results

Completed

An Open-label, Phase II Study of AZD4635 in Patients With Prostate Cancer

NCT04089553

Conditions
Genital Diseases, Genital Diseases, Male, Genital Neoplasms, Male, +9 more
Locations
  • Research Site Denver, Colorado, United States
  • Research Site Fort Myers, Florida, United States
  • Research Site St. Petersburg, Florida, United States
  • Research Site West Palm Beach, Florida, United States
View Trial Details
Completed

Safety, Tolerability and Pharmacokinetics of ONC1-0013B in Patients With Progressive Metastatic Castration-resistant Prostate Cancer

NCT03074032

Conditions
Metastatic Castration-resistant Prostate Cancer (mCRPC)
Locations
  • Research Institute of Urology and Interventional Radiology n.a. N.A. Lopatkin (branch of FSBI NMRRC of the Ministry of Health of the Russian Federation) Moscow, Russia
  • Medical Radiological Research Center n.a. A.F. Tsyb (branch of FSBI NMRRC of the Ministry of Health of the Russian Federation) Obninsk, Russia
View Trial Details
Active, Not Recruiting

Study of Lutetium (177Lu) Vipivotide Tetraxetan in mCRPC Participants With Moderately and Severely Impaired and With Normal Renal Function

NCT06004661

Conditions
Female Urogenital Diseases, Female Urogenital Diseases and Pregnancy Complications, Kidney Diseases, +5 more
Locations
  • Mount Sinai Hosp Med School New York, United States
  • Novartis Investigative Site Paris, France
  • Novartis Investigative Site Vandœuvre-lès-Nancy, France
  • Novartis Investigative Site Essen, Germany
View Trial Details
Active, Not Recruiting

A Study Evaluating [177Lu]Lu-PSMA-617 vs. a Change of Androgen Receptor-directed Therapy in Taxane Treatment Naive Chinese Male Patients With Progressive Metastatic Castrate Resistant Prostate Cancer

NCT05658003

Conditions
Metastatic Castration-resistant Prostate Cancer (mCRPC)
Locations
  • Novartis Investigative Site Wuhan, Hubei, China
  • Novartis Investigative Site Nanjing, Jiangsu, China
  • Novartis Investigative Site Nanjing, Jiangsu, China
  • Novartis Investigative Site Shenyang, Liaoning, China
View all 15 locations
View Trial Details

Related conditions